CG Oncology spotlights oncolytic virus combo data ahead of full readout due next year

CG Oncology has been quietly chugging along — only giving updates at sequential cancer conferences ahead of a full readout on its oncolytic virus cancer therapy next year.

In its latest at SITC, the Irvine, CA-based biotech showed up with longer-term data on its therapy, CG0070, in combination with Merck’s...

Click to view original post